Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound ...

In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.  | In a remarkable turnaround, ...

Novo Nordisk has made Omnicom the agency of record for U.S. media buying, ending the drugmaker’s six-year partnership with ...

It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...

Fresenius Kabi voluntarily recalled one lot of morphine sulfate injection due to a labeling mix-up with prefilled syringes of the opioid dilaudid that could trigger an overdose resulting in severe ...

Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...

Takeda's first-in-class orexin treatment won an FDA nod in narcolepsy. Daiichi Sankyo faced investor pushback after admitting ...

Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine.  | Despite a major curveball thrown by the ...

After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton ...

Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change ...

With Bayer’s pharma sales growth lagging behind its crop science and consumer health divisions in the second quarter, analysts once again raised the possibility of major changes to the German ...

Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing ...